Eli Lilly raises forecast after boost in Zepbound, Mounjaro sales

Eli Lilly and Co.'s second-quarter earnings surpassed Wall Street estimates as sales of its blockbuster weight-loss drugs soared.  "Mounjaro, Zepbound and Verzenio led our strong financial performance in the second quarter as we advanced our manufacturing expansion agenda," CEO David Ricks said in a statement. During the three-month period, Lilly notched $11.3 billion in global revenue, surpassing the $9.92 billion that Wall Street expected. Adjusted earnings per share came in at $3.92, which also beat Wall ...